Mylan Inc. (MYL) said its subsidiary Mylan Pharmaceuticals Inc. has launched Escitalopram Tablets USP, 5 mg, 10 mg and 20 mg, the first equivalent product to Forest Laboratories' (FRX) Lexapro.
Lexapro is used for acute and maintenance treatment of major depressive disorder and acute treatment of generalized anxiety disorder.
Mylan will market this product exclusively until the expiration of the pediatric exclusivity on the compound patent, as per the settlement agreement between Mylan's Alphapharm subsidiary and Forest Laboratories Inc.
by RTT Staff Writer
For comments and feedback: firstname.lastname@example.org